4.7 Article Proceedings Paper

Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group

Journal

ANNALS OF ONCOLOGY
Volume 19, Issue 8, Pages 1477-1484

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdn147

Keywords

clinical heterogeneity; NK/T-cell lymphoma; prognostic factor

Categories

Funding

  1. Korea Health Promotion Institute [A062260, A050564, A070001] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
  2. National Research Foundation of Korea [R13-2002-025-01001-0] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Background: This national survey was undertaken to propose the classification of extranodal natural killer (NK)/T-cell lymphoma (NTCL) subtypes and to clarify a clinical heterogeneity. Patients and methods: Two hundred and eighty patients newly diagnosed as NTCL were enrolled from 22 Korean medical centers. Two subsets were compared: one involving the upper aerodigestive tract (UAT) and another involving the non-upper aerodigestive tract (NUAT) region, which comprises the skin, gastrointestinal tract, and liver or soft tissues. Clinical prognostic factors, survival outcomes, and independent predictors for survival were compared between each subset. Results: NUAT-NTCL (59 patients) had significantly higher proportions of disseminated disease, aggressive biologic features, and unfavorable host reactions compared with UAT-NTCL (221 patients). NUAT-NTCL had shortened 5-year overall survival (OS) (22% versus 41%, P = 0.001). Ann Arbor staging, the International Prognostic Index, and the NTCL prognostic index failed to predict the OS of NUAT-NTCL, but did predict the OS in UAT-NTCL. Independent predictors for OS by multivariate analyses differed between each subset. In the NUAT subset, extranodal sites and regional nodes predicted the OS, while Ann Arbor staging, age, performance status, and lactate dehydrogenase level predicted the OS in the UAT subset. Conclusion: NUAT-NTCL may represent a distinctive disease entity in terms of clinical factors, independent predictors, and survival outcomes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Medicine, General & Internal

Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma

Hyerim Ha, Bhumsuk Keam, Chan-Young Ock, Tae Min Kim, Jin Ho Kim, Eun-Jae Chung, Seong Keun Kwon, Soon-Hyun Ahn, Hong-Gyun Wu, Myung-Whun Sung, Dae Seog Heo

Summary: The study demonstrated that concurrent chemoradiation with cisplatin is effective for local control of locally advanced unresectable ACC, achieving high rates of complete remission with manageable toxicity.

KOREAN JOURNAL OF INTERNAL MEDICINE (2021)

Article Medicine, General & Internal

Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer

Chang Hyun Nam, Jaemoon Koh, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo

Summary: The study found that about one-fourth of non-small cell lung cancer patients experienced changes in their PD-L1 expression status. Patients with PD-L1 positivity in either archival or recent samples showed better responses to immune checkpoint inhibitors and longer overall survival after platinum failure compared to those who maintained PD-L1 negativity.

KOREAN JOURNAL OF INTERNAL MEDICINE (2021)

Article Oncology

Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy

Changhee Park, Kyeonghun Jeong, Joon-Hyeong Park, Sohee Jung, Jeong Mo Bae, Kwangsoo Kim, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Se-Hoon Lee, Ju-Seog Lee, Dong-Wan Kim, Gyeong Hoon Kang, Doo Hyun Chung, Dae Seog Heo

Summary: The study demonstrated a negative correlation between overall methylation aberrancy and tumor immunogenicity, indicating the importance of methylation aberrancy for tumors to evade immune surveillance. This highlights the need for further development of methylation biomarkers in cancer research.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Article Oncology

Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues

Shin Hye Yoo, Jihui Yun, Bhumsuk Keam, Seung-Pyo Hong, Chan-Young Ock, Jaemoon Koh, Sehui Kim, Yoon Kyung Jeon, Kyeong Cheon Jung, Miso Kim, Tae Min Kim, Dong-Wan Kim, Jong-Il Kim, Dae Seog Heo

Summary: The increase in immunosuppressive markers observed after ICI treatment may contribute to acquired resistance (AR), and APOBEC-mediated PIK3CA mutation could be another mechanism of AR. Further studies with sufficient sample size are needed to validate these mechanisms.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Article Oncology

Analysis of Cancer Patient Decision-Making and Health Service Utilization after Enforcement of the Life-Sustaining Treatment Decision-Making Act in Korea

Dalyong Kim, Shin Hye Yoo, Seyoung Seo, Hyun Jung Lee, Min Sun Kim, Sung Joon Shin, Chi-Yeon Lim, Do Yeun Kim, Dae Seog Heo, Chae-Man Lim

Summary: This study analyzed the decision-making patterns for life-sustaining treatment (LST) and medical service utilization changes after the enforcement of the Life-Sustaining Treatment Decision-Making Act. The results showed that the cancer patient's own decision-making was associated with earlier decision-making, less use of certain critical treatments, and lower medical costs.

CANCER RESEARCH AND TREATMENT (2022)

Article Oncology

Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer

Chaelin Lee, Miso Kim, Dong-Wan Kim, Tae Min Kim, Soyeon Kim, Sun-Wha Im, Yoon Kyung Jeon, Bhumsuk Keam, Ja-Lok Ku, Dae Seog Heo

Summary: This study reveals that the T790M mutation in EGFR-KDD confers resistance to 1st and 2nd generation EGFR tyrosine kinase inhibitors (TKIs), but is sensitive to 3rd generation EGFR TKIs. In addition, the study identifies that the C797S mutation in kinase domain 2 of EGFR-KDDT790M mediates a resistance mechanism against 3rd generation EGFR TKIs.

CANCER RESEARCH AND TREATMENT (2022)

Article Critical Care Medicine

Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab

Jun Won Park, Jeffrey R. Curtis, Kang Il Jun, Tae Min Kim, Dae Seog Heo, Jongwon Ha, Kyung-Suk Suh, Kwang-Woong Lee, Hajeong Lee, Jaeseok Yang, Min Jung Kim, Yunhee Choi, Eun Bong Lee

Summary: The use of TMP-SMX prophylaxis significantly reduces the incidence of PJP in patients receiving rituximab treatment, with an acceptable safety profile.

CHEST (2022)

Article Multidisciplinary Sciences

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment

So Yeon Oh, Soyeon Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo

Summary: The study revealed that high levels of sPD-L1 in cancer patients were associated with progressive disease and worse prognosis, as well as positively correlated with neutrophil to lymphocyte ratios and negatively correlated with lymphocyte proportions and total numbers.

SCIENTIFIC REPORTS (2021)

Article Multidisciplinary Sciences

Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis

Ha-Ram Park, Seong-Eun Kim, Bhumsuk Keam, Hyewon Chung, Seung Hyeok Seok, Soyeon Kim, Miso Kim, Tae Min Kim, Junsang Doh, Dong-Wan Kim, Dae Seog Heo

Summary: This study provides evidence that anti-CD47 blocking antibodies enhance the antitumor effect of macrophages in renal cell carcinoma (RCC), and their combination with VEGFR TKIs can be a potential therapeutic strategy.

SCIENTIFIC REPORTS (2022)

Article Health Care Sciences & Services

Aggressiveness of care in the last days of life in the emergency department of a tertiary hospital in Korea

Jung Sun Kim, Sun Young Lee, Min Sung Lee, Shin Hye Yoo, Jeongmi Shin, Wonho Choi, Yejin Kim, Hyung Sook Han, Jinui Hong, Bhumsuk Keam, Dae Seog Heo

Summary: This study investigated the characteristics of end-of-life care for dying patients in the emergency department (ED) of a tertiary hospital in Korea. The findings showed that patients in the ED received more aggressive care and less comfort care, with lower involvement of palliative care teams. Younger patients and those who completed life-sustaining treatment legal forms received more comfort care.

BMC PALLIATIVE CARE (2022)

Article Infectious Diseases

The impact of palliative care consultation on reducing antibiotic overuse in hospitalized patients with terminal cancer at the end of life: a propensity score-weighting study

Jeong-Han Kim, Shin Hye Yoo, Bhumsuk Keam, Dae Seog Heo

Summary: Palliative care consultation may reduce aggressive antibiotic use in hospitalized patients with terminal cancer during the end-of-life phase.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Oncology

Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines

Jeongjae Lee, Bhumsuk Keam, Ha-Ram Park, Ji-Eun Park, Soyeon Kim, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo

Summary: This study found a correlation between HLA-E surface expression in head and neck squamous cell carcinoma cell lines and the efficacy of the NKG2A inhibitor, monalizumab, in promoting NK cell activity. Cell lines with high HLA-E expression showed stronger inhibition of NK cell cytotoxicity and had higher efficacy of monalizumab. Combination with cetuximab increased the effectiveness of monalizumab. Stimulation of isolated NK cells with IL-2 and IL-15 also increased the efficacy of monalizumab, even in the HLA-E low groups.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Article Oncology

The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell lines

Jeongjae Lee, Bhumsuk Keam, Soyeon Kim, Jung-Nyoung Heo, Eunkyo Joung, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo

Summary: A novel GCN2 inhibitor, AST-0513, was found to inhibit the GCN2-ATF4 pathway, reduce proliferation, induce cell cycle arrest and apoptosis in head and neck squamous cell carcinoma cell lines, suggesting its potential as a therapeutic option.

TRANSLATIONAL ONCOLOGY (2023)

Meeting Abstract Oncology

Treatment strategies based on the molecular subtypes of transformed small cell lung cancer (t-SCLC)

S. Oh, J. Koh, T. M. Kim, S. Kim, J. Youk, M. Kim, B. Keam, Y. K. Jeon, D. W. Kim, D. S. Heo

EUROPEAN JOURNAL OF CANCER (2022)

Meeting Abstract Oncology

Mechanisms of resistance to mobocertinib in EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC)

S. Park, T. M. Kim, S. Kim, M. Kim, B. Keam, D. W. Kim, D. S. Heo

EUROPEAN JOURNAL OF CANCER (2022)

No Data Available